The news is directly about Celldex Therapeutics. The maintained Overweight rating indicates that the analyst still has a positive outlook on the company, which could be positive for the stock. However, the lowered price target might indicate a slightly less optimistic view on the company's future performance, which could have a neutral to slightly negative impact on the stock price in the short term.